Rationale for and role of thiazolidinediones in type 2 diabetes mellitus

被引:0
|
作者
Lebovitz, HE [1 ]
机构
[1] SUNY Hlth Sci Ctr, Dept Med, Div Endocrinol, Brooklyn, NY 11203 USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2002年 / 90卷 / 5A期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several classes of antihyperglycemic agents are available for the treatment of patients with type 2 diabetes. These agents, including thiazolidinediones, biguanides, insulin secretagogues, alpha-glucosidase inhibitors, and insulin, offer differing mechanisms of actions and can be used either alone or in combination. The thiazolidinediones are a newer class of oral antidiabetic agents that improve glycemic control and may preserve beta-cell function. Clinical trial data suggest that patients with type 2 diabetes experience progressive deterioration of beta-cell function. By decreasing insulin resistance, thiazolidinediones may preserve beta-cell function, and patients may experience prolonged glycemic control. The thiazolidinediones also exert beneficial effects on dyslipidemia, endothelial function, coagulation, and blood pressure. By improving these components of the metabolic syndrome, thiazolidinediones may reduce the incidence of both microvascular and macrovascular complications. This article provides an overview of the role of thiazolidinediones in the treatment of type 2 diabetes. (C) 2002 by Excerpta Medica, Inc.
引用
收藏
页码:34G / 41G
页数:8
相关论文
共 50 条
  • [31] Molecular Remodeling of the Insulin Receptor Pathway by Thiazolidinediones in Type 2 Diabetes Mellitus: A Brief Review
    Sahajpal, Nikhil S.
    Jain, Subheet K.
    PROTEIN AND PEPTIDE LETTERS, 2016, 23 (09): : 836 - 847
  • [32] Thiazolidinediones for initial treatment of type 2 diabetes?
    Nathan, David M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23): : 2477 - 2480
  • [33] Thiazolidinediones and blood lipids in type 2 diabetes
    van Wijk, JPH
    de Koning, EJP
    Martens, EP
    Rabelink, TJ
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (10) : 1744 - 1749
  • [34] Thiazolidinediones and cardiovascular outcomes in type 2 diabetes
    Singh, Sonal
    Furberg, Curt D.
    HEART, 2009, 95 (01) : 1 - 3
  • [35] Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus
    Filion, Kristian B.
    Joseph, Lawrence
    Boivin, Jean-Francois
    Suissa, Samy
    Brophy, James M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (08) : 785 - 796
  • [36] Thiazolidinediones and its negative effects on bone metabolism in Brazilian individuals with type 2 diabetes mellitus
    Hirata, M. H.
    Himelfarb, S. T.
    Marques, M. F.
    Silva, F. A.
    Rodrigues, A. C.
    Sampaio, M. F.
    Dinkhuysen, J. F.
    Bertolami, M. C.
    Armaganijan, D.
    Silva, V. F.
    Rezende, A. A.
    Del Monaco, M. I.
    Hirata, R. D.
    CLINICAL CHEMISTRY, 2009, 55 (06) : A223 - A223
  • [37] How beneficial are thiazolidinediones for diabetes mellitus?
    Culhane, NS
    Graves, R
    JOURNAL OF FAMILY PRACTICE, 2002, 51 (05): : 424 - 424
  • [38] Thiazolidinediones and clinical outcomes in type 2 diabetes
    Retnakaran, Ravi
    Zinman, Bernard
    LANCET, 2009, 373 (9681): : 2088 - 2090
  • [39] Type 2 diabetes, thiazolidinediones, and cardiovascular risk
    Taylor, Clare
    Hobbs, F. D. Richard
    BRITISH JOURNAL OF GENERAL PRACTICE, 2009, 59 (564): : 520 - 524
  • [40] The Role of MIF in Type 1 and Type 2 Diabetes Mellitus
    Sanchez-Zamora, Yuriko I.
    Rodriguez-Sosa, Miriam
    JOURNAL OF DIABETES RESEARCH, 2014, 2014